Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the incidence of ocular toxicity such as keratopathy and blurred vision associated with the use of antibody-drug conjugates (ADCs). Dr Weisel explains that this toxicity appears to be reversible with the use of prescribed eye drops at the initiation of treatment and by prolonging the interval between treatment. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

свернуть